JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Novavax Inc

Closed

SectorHealthcare

8.54 2.77

Overview

Share price change

24h

Current

Min

8.49

Max

8.6

Key metrics

By Trading Economics

Income

-412M

107M

Sales

-427M

239M

P/E

Sector Avg

3.647

37.461

Profit margin

44.519

Employees

952

EBITDA

-395M

121M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+34.98% upside

Dividends

By Dow Jones

Next Earnings

12 Nov 2025

Market Stats

By TradingEconomics

Market Cap

334M

1.4B

Previous open

5.77

Previous close

8.54

News Sentiment

By Acuity

45%

55%

128 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Novavax Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Apr 2025, 17:06 UTC

Major Market Movers

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status

31 Mar 2025, 14:19 UTC

Major Market Movers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

4 Feb 2025, 18:52 UTC

Major Market Movers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

11 Nov 2024, 14:05 UTC

Major Market Movers

Novavax to Move Forward With Covid-19, Influenza Vaccine After FDA Lifts Clinical Hold

19 May 2025, 14:30 UTC

Top News

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker. -- Barrons.com

19 May 2025, 13:27 UTC

Top News

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker. -- Barrons.com

8 May 2025, 17:55 UTC

Earnings

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8 May 2025, 15:12 UTC

Earnings

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

28 Apr 2025, 17:04 UTC

Earnings

Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot. -- Barrons.com

30 Dec 2024, 23:02 UTC

Acquisitions, Mergers, Takeovers

Novavax Completes Previously Announced $200M Sale of Czech Republic Manufacturing Site to Novo Nordisk

4 Dec 2024, 07:09 UTC

Acquisitions, Mergers, Takeovers

Novavax: Agreement to Close by Dec 30 >NVAX

4 Dec 2024, 07:08 UTC

Acquisitions, Mergers, Takeovers

Novavax: Sale Aligns With Plan to Become More Lean Organization, Drive Value From Pipeline Assets & Tech Platform >NVAX

4 Dec 2024, 07:07 UTC

Acquisitions, Mergers, Takeovers

Novavax: Deal to Also Reduce Annual Operating Costs by About $80M >NVAX

4 Dec 2024, 07:06 UTC

Acquisitions, Mergers, Takeovers

Novavax to Get $190M Cash Payment in 2024, Additional $10M in 2025 >NVAX

4 Dec 2024, 07:06 UTC

Acquisitions, Mergers, Takeovers

Novavax: Agreement Provides Company With Significant, Non-Dilutive Capital >NVAX

4 Dec 2024, 07:04 UTC

Acquisitions, Mergers, Takeovers

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200M

15 Nov 2024, 13:34 UTC

Top News

Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too -- WSJ

15 Nov 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

Peer Comparison

Price change

Novavax Inc Forecast

Price Target

By TipRanks

34.98% upside

12 Months Forecast

Average 11.5 USD  34.98%

High 19 USD

Low 6 USD

Based on 6 Wall Street analysts offering 12 month price targets forNovavax Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

3

Buy

1

Hold

2

Sell

Technical Score

By Trading Central

5.692 / 6.039Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

128 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat